Our Work

Latham & Watkins Advises the Underwriters in AIM Vaccine’s Hong Kong IPO

October 7, 2022

Capital markets team represents the underwriters on global offering of the largest private vaccine corporation in China.

Latham & Watkins has advised the underwriters Goldman Sachs, CICC, China Securities International, and Macquarie on AIM Vaccine Co., Ltd.(AIM Vaccine)’s initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). The global offering consisted of 9,714,000 H shares (subject to the over-allotment option) at an offer price of HK$16.16 per share.

AIM Vaccine is the largest private vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines). It covers the full value chain from research and development, to manufacturing and to commercialization.

The Latham team was led by Hong Kong corporate partners Cathy Yeung and Daying Zhang, with counsel Mandy Wong, associates Chimmy Tao and Carson Wong, and foreign legal consultants Yongshi (Cassey) Wu, Weihao Huang and Zhangmeng (Caroline) Lin.